DrugPatentWatch Database Preview
Drugs with Dosage:
» See Plans and Pricing
Drugs with Dosage:
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration | Dosage |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Fresenius Kabi Usa | POTASSIUM CHLORIDE 10MEQ | potassium chloride | INJECTABLE;INJECTION | 211087-001 | Sep 9, 2020 | AP | RX | No | No | Start Trial | Start Trial | Start Trial | INJECTABLE;INJECTION | |||
Fresenius Kabi Usa | POTASSIUM CHLORIDE 10MEQ | potassium chloride | INJECTABLE;INJECTION | 211087-002 | Sep 9, 2020 | AP | RX | No | No | Start Trial | Start Trial | Start Trial | INJECTABLE;INJECTION | |||
Fresenius Kabi Usa | POTASSIUM CHLORIDE 20MEQ | potassium chloride | INJECTABLE;INJECTION | 211087-003 | Sep 9, 2020 | AP | RX | No | No | Start Trial | Start Trial | Start Trial | INJECTABLE;INJECTION | |||
Fresenius Kabi Usa | POTASSIUM CHLORIDE 40MEQ | potassium chloride | INJECTABLE;INJECTION | 211087-004 | Sep 9, 2020 | AP | RX | No | No | Start Trial | Start Trial | Start Trial | INJECTABLE;INJECTION | |||
Glaxosmithkline | TRELEGY ELLIPTA | fluticasone furoate; umeclidinium bromide; vilanterol trifenatate | POWDER;INHALATION | 209482-002 | Sep 9, 2020 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | POWDER;INHALATION | ||||
Glaxosmithkline | TRELEGY ELLIPTA | fluticasone furoate; umeclidinium bromide; vilanterol trifenatate | POWDER;INHALATION | 209482-002 | Sep 9, 2020 | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | POWDER;INHALATION | |||
Glaxosmithkline | TRELEGY ELLIPTA | fluticasone furoate; umeclidinium bromide; vilanterol trifenatate | POWDER;INHALATION | 209482-002 | Sep 9, 2020 | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | POWDER;INHALATION | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration | >Dosage |